Alpine Immune Sciences 将来の成長

Future 基準チェック /26

Alpine Immune Sciencesの収益は年間9.9%で減少すると予測されていますが、年間収益は年間34.2%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に-78.4% 11%なると予測されています。

主要情報

-9.9%

収益成長率

-11.0%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	34.2%
将来の株主資本利益率	-78.4%
アナリストカバレッジ	Good
最終更新日	17 May 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:34LA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	10	-149	-173	-150	7
12/31/2025	20	-110	-140	-113	8
12/31/2024	18	-97	-96	-91	7
3/31/2024	57	-37	-81	-81	N/A
12/31/2023	59	-32	-79	-79	N/A
9/30/2023	31	-57	-77	-77	N/A
6/30/2023	29	-59	-78	-77	N/A
3/31/2023	26	-64	-76	-75	N/A
12/31/2022	30	-58	-44	-44	N/A
9/30/2022	32	-54	-42	-42	N/A
6/30/2022	32	-54	4	5	N/A
3/31/2022	34	-47	6	6	N/A
12/31/2021	23	-50	-15	-15	N/A
9/30/2021	25	-42	-10	-10	N/A
6/30/2021	18	-34	-46	-45	N/A
3/31/2021	11	-33	23	24	N/A
12/31/2020	9	-28	29	30	N/A
9/30/2020	5	-28	33	34	N/A
6/30/2020	3	-33	28	29	N/A
3/31/2020	3	-35	-35	-34	N/A
12/31/2019	2	-42	-36	-35	N/A
9/30/2019	1	-47	-39	-39	N/A
6/30/2019	1	-48	-36	-36	N/A
3/31/2019	0	-44	-35	-35	N/A
12/31/2018	1	-36	-29	-28	N/A
9/30/2018	1	-30	-25	-25	N/A
6/30/2018	1	-15	-23	-22	N/A
3/31/2018	1	-11	-19	-19	N/A
12/31/2017	2	-8	N/A	-17	N/A
9/30/2017	2	-5	N/A	-13	N/A
6/30/2017	3	-7	N/A	-9	N/A
3/31/2017	3	-3	N/A	-6	N/A
12/31/2016	3	-1	N/A	-4	N/A
12/31/2015	0	0	N/A	5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 34LA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 34LA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 34LA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 34LAの収益 ( 34.2% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 34LAの収益 ( 34.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 34LA 3 年以内に赤字になると予測されています。

Alpine Immune Sciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Full year 2023 earnings released: US$0.64 loss per share (vs US$1.73 loss in FY 2022)

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New major risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.60 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$1.73 loss per share (vs US$1.98 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2021)

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2021)

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought €84k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)

Alpine Immune Sciences Announces First Patient Dosed in Synergy, Alpn-101 Phase 2 Lupus Clinical Trial and $45 Million in Development Milestones Achieved Under Abbvie Collaboration

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at 2021 American Society of Clinical Oncology Virtual Annual Meeting

Alpine Immune Sciences, Inc. Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.30 loss in 1Q 2020)

Full year 2020 earnings released: US$1.34 loss per share (vs US$2.28 loss in FY 2019)

Alpine Immune Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Alpine Immune Sciences, Inc. Announces Executive Changes

New 90-day high: €11.80

Alpine Immune Sciences Appoints Natasha A. Hernday to its Board of Directors

New 90-day high: €7.70

Independent Director recently bought €68k worth of stock

Third quarter 2020 earnings released: US$0.28 loss per share

Revenue misses expectations

Alpine Immune Sciences, Inc. to Report Q3, 2020 Results on Nov 12, 2020

First half earnings released

Alpine Immune Sciences, Inc. announced that it has received $60.000012 million in funding from a group of investors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘